Every Form 4 that Calidi Biotherapeutics, Inc. (CLDI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLDI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDI filings page.
Calidi Biotherapeutics, Inc. (CLDI) reported that director George Peoples received a grant of 4,000 non-qualified stock options on August 17, 2026. These options have an exercise price of $1.36 per share, expire on August 17, 2036, and vest in 1/12 monthly over one year under Calidi’s 2023 Equity Incentive Plan and non-employee director compensation policy. The reported post-transaction derivative holdings of 4,000 options relate only to this grant and do not include options previously granted.
Calidi Biotherapeutics, Inc. (CLDI) reported that director Scott Leftwich received a grant of non-qualified stock options covering 4,000 shares of common stock on August 17, 2026. The options have an exercise price of $1.36 per share, vest in 1/12th monthly over one year starting on the grant date, and expire on August 17, 2036. Following this grant, the filing shows 4,000 options held from this award, excluding any options previously granted.
Calidi Biotherapeutics, Inc. (CLDI) reported that director Alan R. Stewart received a grant of non-qualified stock options for 4,000 shares of common stock. The options have an exercise price of $1.36 per share, expire on August 17, 2036, and were issued under the company’s 2023 Equity Incentive Plan pursuant to its non-employee director compensation policy.
The options vest and become exercisable in 1/12th per month over one year starting on the August 17, 2026 grant date. Following this grant, the reported derivative holdings from this award total 4,000 options, excluding any options previously granted to the director.
Calidi Biotherapeutics, Inc. (CLDI) reported that its Chief Financial Officer, Jackson Andrew C., received a grant of 14,000 incentive stock options to purchase common stock. The options have an exercise price of $1.36 per share, equal to the closing price on August 17, 2026, and expire on August 17, 2036. Under the company’s 2023 Equity Incentive Plan, 25% of the options vest on the one-year anniversary of August 17, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. This grant does not include any incentive stock options previously awarded to the officer.
Calidi Biotherapeutics, Inc. (CLDI) reported that director James A. Schoeneck received a grant of 5,000 non-qualified stock options on August 17, 2026. The options have an exercise price of $1.36 per share, vest in 1/12th monthly over one year, expire on August 17, 2036, and were issued under Calidi’s 2023 Equity Incentive Plan pursuant to its non-employee director compensation policy. Following this grant, Schoeneck holds 5,000 options reported here, which do not include options previously granted.
Calidi Biotherapeutics, Inc. (CLDI) reported that its Chief Executive Officer, Eric E. Poma, received a grant of 32,000 incentive stock options under the company’s 2023 Equity Incentive Plan. The options have a $1.36 exercise price, vest over four years based on continued service, and expire on August 17, 2036. This grant does not include any options previously awarded to him.
Calidi Biotherapeutics, Inc. (CLDI) reported that Chief Scientific Officer Antonio Fernandez Santidrian received a grant of 16,000 incentive stock options under the company’s 2023 Equity Incentive Plan. The options have an exercise price of $1.36 per share and expire on August 17, 2036.
According to the vesting schedule, 25% of the options vest on the one-year anniversary of August 17, 2026, and the remaining 75% vest in equal monthly installments over 36 months, subject to continued service. The filing notes this grant does not include incentive stock options previously granted to the reporting person.
Calidi Biotherapeutics, Inc. (CLDI) reported that director Sanders Corazon (Corsee) D. received a grant of non-qualified stock options on August 17, 2026. The grant covers 6,000 options to purchase common stock at an exercise price of $1.36 per share, equal to the closing price on the grant date. These options vest and become exercisable in 1/12th monthly installments over one year, starting on the grant date, and expire on August 17, 2036. The options were granted under Calidi’s non-employee director compensation policy and issued pursuant to its 2023 Equity Incentive Plan. The reported post-transaction holding of 6,000 options reflects only this grant and does not include options previously granted to the director.
Calidi Biotherapeutics director Allan Camaisa reported an insider sale of the company’s common stock. On 12/12/2025, AJC Capital, LLC, which is controlled by Camaisa, sold 850 shares of Calidi Biotherapeutics common stock at $1.455 per share. The filing states that these sales were made for estate and tax planning purposes.
After this transaction, Camaisa is reported to beneficially own 76,952 shares of common stock. This includes 6,394 shares held directly, 19,860 shares held by AJC Capital, LLC, and 50,698 shares held by Jamir Trust. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust, so he is deemed to beneficially own the shares held by those entities. All share figures give retrospective effect to a 1-for-12 reverse stock split that became effective on August 4, 2025.